FDA Expands Optune’s Glioblastoma Multiforme Indication

The FDA recently approved drug, Optune, in combination with temozolomide for patients with newly diagnosed GBMs. This treatment has increased survival rate by 3 months, compared to conventional treatment. Read the full article.

Leave a Reply